Boston Scientific appoints COO as Boston Scientific stock costs EUR 40.47 before results

Published on 10/21/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year. Boston Scientific stock costs EUR 40.47 on October 21, 2026 before October 28 results.

Leadership transition and earnings test

Boston Scientific appointed Joseph M. Fitzgerald on October 7, 2026, effective January 1, 2027.
Second-quarter 2026 revenue reached USD 5.44 billion, up 7.50 percent year over year.
Boston Scientific stock trades at EUR 40.47 at 11:48 a.m. CEST at Lang & Schwarz on October 21, 2026.

Fotorealistischer Glasturm im Bostoner Finanzviertel, Hafenpanorama im Hintergrund — Boston Properties US1011371077 zeigt einen modernen Glasturm im Bostoner Finanzviertel mit Hafenblick, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US1011371077) trades at EUR 40.47 at Lang & Schwarz on October 21, 2026, as the medical-device maker approaches its next quarterly report. Boston Scientific announced on October 7, 2026, that Joseph M. Fitzgerald will become executive vice president and chief operating officer on January 1, 2027.

Leadership changes before results

The appointment gives investors a concrete management date before the third-quarter report. The filing says Fitzgerald joined Boston Scientific in 1990 and will oversee global operations, business units and regions from January 1, 2027. His annual base salary will be USD 1.05 million, according to the SEC filing dated October 1, 2026.

What will earnings reveal?

Boston Scientific's second-quarter 2026 performance sets the comparison point. MarketBeat reported revenue of USD 5.44 billion for the quarter, up 7.50 percent year over year, while adjusted earnings per share reached USD 0.86 versus USD 0.83 expected. Management had guided third-quarter adjusted earnings per share to USD 0.80-0.82.

Earnings Whispers wrote on October 20, 2026, that consensus stood at USD 0.76 adjusted earnings per share and USD 5.17 billion in revenue for the third quarter. The report also said Boston Scientific had lowered full-year adjusted earnings-per-share guidance to USD 3.28-3.32 after two revisions.

Three dates define the timeline

On July 29, 2026, Boston Scientific reported USD 5.44 billion in second-quarter revenue and USD 0.86 adjusted earnings per share. On October 1, 2026, its regulatory filing documented a USD 1.05 million annual base salary for the incoming chief operating officer. On October 7, 2026, the company announced Fitzgerald's promotion, effective January 1, 2027.

Dates investors can mark

The next substantiated reporting date is October 28, 2026, for third-quarter results. January 1, 2027, is the effective date for Fitzgerald's new operating role.

Stock price before the report

The EUR 40.47 Lang & Schwarz quote gives the stock a clear German-market reference before the earnings event. Boston Scientific's primary listing is on the NYSE, while the company operates in healthcare and medical devices.

Boston Scientific was trading at EUR 40.47 at Lang & Schwarz on October 21, 2026 at 11:48 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.